← FDA DRUG APPROVALS

FDA ANDA · ANDA076341

PRAVASTATIN SODIUM

Sponsor: APOTEX

APPLICATION
ANDA076341
TYPE
ANDA
ORIGINAL APPROVAL
2006-10-23
LATEST ACTION
2025-02-18
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

PRAVASTATIN SODIUMPrescription
PRAVASTATIN SODIUM 40MG · TABLET · ORAL
PRAVASTATIN SODIUMPrescription
PRAVASTATIN SODIUM 10MG · TABLET · ORAL
PRAVASTATIN SODIUMPrescription
PRAVASTATIN SODIUM 80MG · TABLET · ORAL
PRAVASTATIN SODIUMPrescription
PRAVASTATIN SODIUM 20MG · TABLET · ORAL

Approval history

2025-02-18Labeling · Supplement 31 · standardAP
2023-04-26Labeling · Supplement 26 · standardAP
2021-03-05Labeling · Supplement 25 · standardAP
2017-07-07Labeling · Supplement 19 · standardAP
2013-07-26Labeling · Supplement 15 · standardAP
2012-07-12Labeling · Supplement 13AP
2007-12-28Labeling · Supplement 2AP
2007-12-28Manufacturing (CMC) · Supplement 1AP
2006-10-23OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →